Standout Papers

Effects of Intensive Glucose Lowering in Type 2 Diabetes 2000 2026 2008 2017 5.4k
  1. Effects of Intensive Glucose Lowering in Type 2 Diabetes (2008)
    Hertzel C. Gerstein, Michael E. Miller et al. New England Journal of Medicine
  2. Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals (2001)
    Hertzel C. Gerstein JAMA
  3. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015)
    Marc A. Pfeffer, Brian Claggett et al. New England Journal of Medicine
  4. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. (2000)
    Hertzel C. Gerstein, Salim Yusuf et al. PubMed
  5. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview (2000)
    Sarah E. Capes, Dereck Hunt et al. The Lancet
  6. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model (2007)
    Erik D. Roberson, Kimberly Scearce‐Levie et al. Science
  7. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. (1999)
    Mário Sérgio Soares de Azeredo Coutinho, Hertzel C. Gerstein et al. Diabetes Care
  8. Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients (2001)
    Sarah E. Capes, Dereck Hunt et al. Stroke
  9. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006)
    Hertzel C. Gerstein, Salim Yusuf et al. The Lancet
  10. Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial (2001)
    Johannes F.E. Mann, Hertzel C. Gerstein et al. Annals of Internal Medicine
  11. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) (2000)
    Sonia S. Anand, Salim Yusuf et al. The Lancet
  12. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials (2021)
    Naveed Sattar, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology
  13. Intensive glucose control and macrovascular outcomes in type 2 diabetes (2009)
    Fiona Turnbull, Carlos Abraira et al. Diabetologia
  14. An initial investigation of the bending and torsional properties of nitinol root canal files (1988)
    Harmeet Walia, William A. Brantley et al. Journal of Endodontics
  15. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2006)
    John B. Buse, Henry N. Ginsberg et al. Diabetes Care
  16. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies (2005)
    Tali Cukierman, Hertzel C. Gerstein et al. Diabetologia
  17. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes (2011)
    Hertzel C. Gerstein New England Journal of Medicine
  18. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction (2000)
    Klas Malmberg, Salim Yusuf et al. Circulation
  19. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (2021)
    Hertzel C. Gerstein, Naveed Sattar et al. New England Journal of Medicine
  20. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks (2018)
    Theingi Aung, Jim Halsey et al. JAMA Cardiology
  21. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials (2017)
    Sophia Zoungas, Hisatomi Arima et al. The Lancet Diabetes & Endocrinology
  22. Canal configuration in the mesiobuccal root of the maxillary first molar and its endodontic significance (1969)
    Franklin S. Weine, Harry J. Healey et al. Oral Surgery Oral Medicine Oral Pathology
  23. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  24. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes (2021)
    Matthew C. Riddle, William T. Cefalu et al. Diabetes Care
  25. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2024)
    Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology

Immediate Impact

9 from Science/Nature 91 standout
Sub-graph 1 of 17

Citing Papers

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
13 intermediate papers

Works of Hertzel C. Gerstein being referenced

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
2021 Standout
Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort
2015
and 6 more

Author Peers

Author Last Decade Papers Cites
Hertzel C. Gerstein 25805 12016 8604 496 49.6k
James R. Sowers 14251 15126 9747 681 41.2k
Steven M. Haffner 32314 14565 10990 517 60.5k
Markku Laakso 22794 12751 15999 667 56.6k
Juliana C.N. Chan 17123 5091 7584 830 37.4k
Coen D.A. Stehouwer 15268 17268 6525 1.0k 55.7k
Bernard Zinman 43046 8689 18193 643 61.2k
Elizabeth Barrett‐Connor 16950 7533 5368 665 48.4k
William C. Knowler 21517 5395 10313 516 56.0k
Jaakko Tuomilehto 22298 12064 6777 757 59.1k
Naveed Sattar 22026 14746 8966 1.2k 70.7k

All Works

Loading papers...

Rankless by CCL
2026